PriceTargets.com logo

McKesson - MCK Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $887.69
  • Forecasted Upside: 9.11%
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 12 Buy Ratings
  • 1 Strong Buy Ratings
$813.61 As of 12/4/2025 04:59 PM ET
▲ +8.24 (1.02%)

This chart shows the closing price for MCK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New McKesson Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MCK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MCK

Analyst Price Target is $887.69
▲ +9.11% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for McKesson in the last 3 months. The average price target is $887.69, with a high forecast of $1,000.00 and a low forecast of $770.00. The average price target represents a 9.11% upside from the last price of $813.61.

This chart shows the closing price for MCK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 17 contributing investment analysts is to moderate buy stock in McKesson. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingBuy (A-) ➝ Buy (A-)
11/25/2025Weiss RatingsReiterated RatingBuy (A-) ➝ Buy (A-)
11/25/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
11/19/2025Weiss RatingsUpgradeBuy (B+) ➝ Buy (A-)
11/13/2025Weiss RatingsReiterated RatingBuy (B+) ➝ Buy (B+)
11/10/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$816.00 ➝ $914.00
11/6/2025Evercore ISIReiterated RatingOutperform ➝ Outperform$1,000.00
11/6/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$873.00 ➝ $927.00
11/6/2025UBS GroupBoost TargetBuy ➝ Buy$920.00 ➝ $980.00
11/6/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$857.00 ➝ $916.00
10/27/2025UBS GroupBoost TargetBuy ➝ Buy$860.00 ➝ $920.00
10/27/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/13/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$820.00 ➝ $900.00
10/8/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
9/27/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
9/26/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$821.00 ➝ $853.00
9/24/2025Evercore ISIBoost TargetOutperform ➝ Outperform$800.00 ➝ $825.00
9/24/2025CowenReiterated RatingBuy ➝ Buy
9/24/2025CitigroupBoost TargetBuy ➝ Buy$820.00 ➝ $860.00
9/24/2025TD CowenBoost TargetBuy ➝ Buy$830.00 ➝ $864.00
9/24/2025MizuhoBoost TargetNeutral ➝ Neutral$750.00 ➝ $770.00
9/24/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$810.00 ➝ $857.00
9/24/2025UBS GroupBoost TargetBuy ➝ Buy$820.00 ➝ $860.00
9/24/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$785.00 ➝ $850.00
9/24/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$772.00 ➝ $816.00
9/24/2025Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$775.00 ➝ $856.00
9/24/2025Bank of AmericaBoost TargetBuy ➝ Buy$800.00 ➝ $850.00
8/13/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$766.00 ➝ $772.00
8/7/2025CowenReiterated RatingBuy ➝ Buy
7/16/2025Morgan StanleyReiterated RatingOverweight ➝ Overweight$770.00 ➝ $810.00
7/9/2025Evercore ISIBoost TargetOutperform ➝ Outperform$760.00 ➝ $800.00
6/11/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$745.00 ➝ $770.00
6/3/2025Wells Fargo & CompanySet TargetEqual Weight ➝ Equal Weight$691.00 ➝ $766.00
5/9/2025Bank of AmericaBoost TargetBuy ➝ Buy$755.00 ➝ $800.00
4/29/2025UBS GroupBoost TargetBuy ➝ Buy$708.00 ➝ $805.00
4/11/2025Bank of AmericaBoost TargetBuy ➝ Buy$665.00 ➝ $755.00
4/4/2025Cfra ResearchDowngradeModerate Buy ➝ Hold
4/3/2025MizuhoBoost TargetNeutral ➝ Neutral$630.00 ➝ $690.00
4/2/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$642.00 ➝ $745.00
3/14/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$641.00 ➝ $691.00
2/6/2025Evercore ISIBoost TargetOutperform ➝ Outperform$650.00 ➝ $675.00
1/10/2025CitigroupLower TargetBuy ➝ Buy$713.00 ➝ $677.00
1/6/2025Bank of AmericaLower TargetBuy ➝ Buy$680.00 ➝ $650.00
12/17/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$612.00 ➝ $642.00
12/13/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$535.00 ➝ $641.00
12/4/2024MizuhoInitiated CoverageNeutral$630.00
11/13/2024CitigroupBoost TargetBuy ➝ Buy$630.00 ➝ $713.00
11/7/2024Baird R WUpgradeHold ➝ Strong-Buy
11/7/2024Evercore ISIBoost TargetOutperform ➝ Outperform$560.00 ➝ $680.00
11/7/2024Robert W. BairdUpgradeNeutral ➝ Outperform$531.00 ➝ $688.00
10/7/2024Leerink PartnersLower TargetOutperform ➝ Outperform$665.00 ➝ $630.00
9/25/2024Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$623.00 ➝ $579.00
9/24/2024Baird R WDowngradeStrong-Buy ➝ Hold
9/24/2024Robert W. BairdReiterated RatingOutperform ➝ Neutral$603.00 ➝ $531.00
9/13/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$576.00 ➝ $535.00
9/10/2024CitigroupLower TargetBuy ➝ Buy$670.00 ➝ $630.00
9/5/2024Leerink PartnersLower TargetOutperform ➝ Outperform$670.00 ➝ $665.00
8/21/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$656.00 ➝ $661.00
8/8/2024BarclaysBoost TargetOverweight ➝ Overweight$596.00 ➝ $616.00
8/8/2024MizuhoBoost TargetNeutral$540.00 ➝ $570.00
8/8/2024Evercore ISILower TargetOutperform ➝ Outperform$660.00 ➝ $630.00
8/8/2024Robert W. BairdLower TargetOutperform ➝ Outperform$694.00 ➝ $671.00
7/19/2024CitigroupBoost TargetBuy ➝ Buy$620.00 ➝ $670.00
7/9/2024Evercore ISIBoost TargetOutperform ➝ Outperform$600.00 ➝ $660.00
7/9/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$679.00 ➝ $694.00
6/25/2024Bank of AmericaBoost TargetBuy ➝ Buy$590.00 ➝ $670.00
6/24/2024ArgusBoost TargetBuy ➝ Buy$570.00 ➝ $670.00
5/9/2024Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$547.00 ➝ $545.00
5/9/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$502.00 ➝ $551.00
5/8/2024BarclaysBoost TargetOverweight ➝ Overweight$571.00 ➝ $596.00
5/8/2024TD CowenBoost TargetBuy ➝ Buy$563.00 ➝ $652.00
5/8/2024Evercore ISIBoost TargetOutperform ➝ Outperform$590.00 ➝ $600.00
5/8/2024UBS GroupBoost TargetBuy ➝ Buy$620.00 ➝ $630.00
5/8/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$603.00 ➝ $671.00
4/30/2024CitigroupBoost TargetBuy ➝ Buy$575.00 ➝ $620.00
4/15/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$522.00 ➝ $548.00
4/10/2024ArgusBoost TargetBuy ➝ Buy$510.00 ➝ $570.00
3/6/2024UBS GroupBoost TargetBuy ➝ Buy$575.00 ➝ $620.00
2/26/2024Leerink PartnrsReiterated RatingOutperform
2/26/2024Leerink PartnersInitiated CoverageOutperform$600.00
2/9/2024MizuhoBoost TargetNeutral ➝ Neutral$450.00 ➝ $505.00
2/8/2024CitigroupBoost TargetBuy ➝ Buy$530.00 ➝ $575.00
1/29/2024UBS GroupBoost TargetBuy ➝ Buy$525.00 ➝ $559.00
1/3/2024BarclaysInitiated CoverageOverweight$537.00
12/14/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$502.00
12/11/2023TD CowenBoost TargetOutperform ➝ Outperform$508.00 ➝ $563.00
11/17/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$495.00 ➝ $514.00
11/3/2023MizuhoBoost TargetNeutral ➝ Neutral$427.00 ➝ $450.00
11/2/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$459.00 ➝ $480.00
10/11/2023Evercore ISIBoost Target$485.00 ➝ $490.00
10/9/2023ArgusBoost TargetBuy ➝ Buy$450.00 ➝ $480.00
8/11/2023Credit Suisse GroupBoost TargetOutperform ➝ Outperform$450.00 ➝ $485.00
8/7/2023TD CowenBoost TargetOutperform ➝ Outperform$491.00 ➝ $495.00
8/3/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$426.00 ➝ $459.00
8/3/2023UBS GroupBoost TargetBuy ➝ Buy$470.00 ➝ $480.00
7/17/2023Bank of AmericaBoost Target$470.00 ➝ $485.00
7/11/2023MizuhoBoost Target$390.00 ➝ $427.00
6/29/2023ArgusBoost Target$430.00 ➝ $450.00
5/12/2023Credit Suisse GroupBoost Target$430.00 ➝ $450.00
5/9/202358.comReiterated RatingMaintains
5/9/2023Bank of AmericaBoost Target$450.00 ➝ $470.00
5/9/2023Robert W. BairdBoost Target$450.00 ➝ $475.00
5/9/2023MizuhoBoost Target$376.00 ➝ $390.00
5/9/2023BarclaysBoost Target$415.00 ➝ $420.00
3/31/2023CitigroupInitiated CoverageBuy$420.00
2/2/2023Morgan StanleyBoost TargetOverweight$420.00 ➝ $426.00
2/2/2023Robert W. BairdBoost TargetOutperform$445.00 ➝ $450.00
1/31/2023UBS GroupLower TargetBuy$450.00 ➝ $440.00
1/11/2023Robert W. BairdBoost TargetOutperform$440.00 ➝ $445.00
1/6/2023Morgan StanleyBoost TargetOverweight$403.00 ➝ $420.00
11/14/2022MizuhoBoost TargetNeutral$345.00 ➝ $376.00
11/2/2022CowenBoost Target$384.00 ➝ $416.00
11/2/2022CowenBoost Target$384.00 ➝ $416.00
11/2/2022BarclaysBoost TargetEqual Weight$375.00 ➝ $415.00
11/2/2022Robert W. BairdBoost TargetOutperform$405.00 ➝ $440.00
10/13/2022Robert W. BairdBoost Target$405.00
9/12/2022ArgusBoost TargetBuy$370.00 ➝ $430.00
8/22/2022Morgan StanleyBoost TargetOverweight$370.00 ➝ $403.00
8/9/2022CowenBoost Target$384.00
8/8/2022Deutsche Bank AktiengesellschaftBoost Target$378.00 ➝ $409.00
8/8/2022Credit Suisse GroupBoost TargetOutperform$377.00 ➝ $385.00
8/4/2022UBS GroupBoost TargetBuy$380.00 ➝ $400.00
8/4/2022Robert W. BairdBoost TargetOutperform$386.00 ➝ $400.00
8/4/2022MizuhoBoost TargetNeutral$331.00 ➝ $345.00
7/6/2022ArgusDowngradeBuy ➝ Hold
6/7/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$343.00 ➝ $378.00
5/19/2022UBS GroupBoost TargetHold$380.00
5/11/2022Credit Suisse GroupBoost Target$333.00 ➝ $377.00
5/10/2022Deutsche Bank AktiengesellschaftBoost Target$270.00 ➝ $343.00
5/9/2022MizuhoBoost Target$280.00 ➝ $331.00
5/6/2022Robert W. BairdBoost Target$352.00 ➝ $380.00
4/18/2022CowenBoost Target$325.00 ➝ $361.00
4/18/2022CowenBoost TargetOutperform$325.00 ➝ $361.00
4/12/2022Morgan StanleyBoost TargetOverweight$292.00 ➝ $370.00
4/1/2022Credit Suisse GroupInitiated CoverageOutperform$333.00
2/8/2022UBS GroupBoost TargetBuy$245.00 ➝ $303.00
2/7/2022MizuhoBoost TargetNeutral$250.00 ➝ $280.00
2/4/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$262.00 ➝ $270.00
2/3/2022Robert W. BairdBoost Target$312.00 ➝ $340.00
1/7/2022Credit Suisse GroupUpgradeNeutral ➝ Outperform$230.00 ➝ $333.00
12/20/2021MizuhoBoost TargetNeutral$236.00 ➝ $250.00
12/17/2021Morgan StanleyBoost TargetOverweight$252.00 ➝ $292.00
12/10/2021Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$279.00 ➝ $262.00
12/9/2021Bank of AmericaBoost TargetBuy ➝ Buy$250.00 ➝ $265.00
12/9/2021Robert W. BairdBoost TargetOutperform ➝ Outperform$280.00 ➝ $300.00
12/9/2021MizuhoBoost TargetNeutral ➝ Neutral$229.00 ➝ $236.00
12/9/2021BarclaysBoost TargetOverweight ➝ Overweight$270.00 ➝ $290.00
12/6/2021Morgan StanleyBoost TargetOverweight$240.00 ➝ $250.00
12/6/2021CowenBoost TargetOutperform ➝ Outperform$268.00 ➝ $300.00
11/8/2021ArgusBoost TargetBuy$230.00 ➝ $270.00
11/8/2021Credit Suisse GroupBoost TargetNeutral$224.00 ➝ $230.00
11/5/2021CowenBoost TargetOutperform$247.00 ➝ $268.00
11/3/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$261.00 ➝ $279.00
11/3/2021MizuhoBoost TargetNeutral$210.00 ➝ $229.00
11/2/2021Evercore ISIBoost TargetOutperform$225.00 ➝ $230.00
11/2/2021Bank of AmericaBoost TargetBuy$237.00 ➝ $250.00
11/2/2021Jefferies Financial GroupBoost TargetBuy$270.00 ➝ $280.00
11/2/2021Robert W. BairdBoost TargetOutperform$254.00 ➝ $260.00
11/2/2021BarclaysBoost TargetOverweight$255.00 ➝ $270.00
10/29/2021Morgan StanleyBoost TargetOverweight$226.00 ➝ $240.00
8/9/2021Credit Suisse GroupBoost TargetNeutral$222.00 ➝ $224.00
8/5/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$237.00 ➝ $261.00
5/12/2021MizuhoBoost TargetNeutral$190.00 ➝ $205.00
5/10/2021Credit Suisse GroupBoost TargetNeutral$192.00 ➝ $222.00
5/7/2021The Goldman Sachs GroupBoost TargetBuy$231.00 ➝ $257.00
5/7/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$231.00 ➝ $237.00
3/30/2021ArgusUpgradeHold ➝ Buy$230.00
3/2/2021CowenBoost TargetPositive ➝ Outperform$210.00 ➝ $224.00
2/3/2021Morgan StanleyBoost TargetOverweight$219.00 ➝ $226.00
2/3/2021Credit Suisse GroupBoost TargetNeutral$178.00 ➝ $192.00
2/3/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$222.00 ➝ $231.00
2/3/2021MizuhoBoost TargetNeutral$178.00 ➝ $190.00
2/1/2021CowenBoost TargetOutperform$186.00 ➝ $210.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.40 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 56 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 137 very positive mentions
  • 33 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 168 very positive mentions
  • 33 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 168 very positive mentions
  • 33 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

McKesson logo
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Read More

Today's Range

Now: $813.61
Low: $803.00
High: $814.69

50 Day Range

MA: $814.51
Low: $738.00
High: $890.30

52 Week Range

Now: $813.61
Low: $558.13
High: $895.58

Volume

880,904 shs

Average Volume

781,831 shs

Market Capitalization

$100.42 billion

P/E Ratio

25.32

Dividend Yield

0.41%

Beta

0.38

Frequently Asked Questions

What sell-side analysts currently cover shares of McKesson?

The following Wall Street analysts have issued stock ratings on McKesson in the last twelve months: Bank of America Corporation, Cfra Research, Citigroup Inc., Cowen Inc, Deutsche Bank Aktiengesellschaft, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Mizuho, Morgan Stanley, Robert W. Baird, TD Cowen, UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for MCK.

What is the current price target for McKesson?

0 Wall Street analysts have set twelve-month price targets for McKesson in the last year. Their average twelve-month price target is $887.69, suggesting a possible upside of 9.1%. Evercore ISI has the highest price target set, predicting MCK will reach $1,000.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $770.00 for McKesson in the next year.
View the latest price targets for MCK.

What is the current consensus analyst rating for McKesson?

McKesson currently has 4 hold ratings, 12 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MCK.

What other companies compete with McKesson?

Other companies that are similar to McKesson include Hologic, HealthEquity, Henry Schein, Merit Medical Systems and AMN Healthcare Services. Learn More about companies similar to McKesson.

How do I contact McKesson's investor relations team?

McKesson's physical mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The company's listed phone number is (972) 446-4800 and its investor relations email address is [email protected]. The official website for McKesson is www.mckesson.com. Learn More about contacing McKesson investor relations.